In 2007 in Nichia v Argos* the UK’s most senior full-time patents judge at the time, Jacob LJ, held that disclosure should no longer be available as a matter of course on standard issues such as obviousness in patent cases. This came as a breath of fresh air to many IP practitioners in the UK…
Practitioners and applicants have been wondering how the USPTO would respond to the July 20, 2012, U.S. Supreme Court decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc., which held that Prometheus’ personalized medicine method claims could not be patented because they were directed to a law of nature, and so excluded from patent-eligibility under 35 USC…
In the decision T 1621/09 of the Boards of Appeal of the EPO, it was decided that late filed arguments of the appellant amended the case to such an extent that their admittance lay within the Board’s discretion, even though the new arguments were based on facts and evidence already in the proceedings. Having found so the Board, exercising its discretion, did not admit the new arguments into the proceedings.
The Higher Regional Court Dusseldorf decided on 26 April 2012 (docket I-2 U 18/12) that the admissibility (under Article 27 BR) of exclusive licensee’s patent infringement action despite pending NDA proceedings against patentee in another Member State depends on whether the declaratory judgment will have the force of res judicata against licensee. This must be…
by Stefan Lieck In the judgement dated 12/01/2012 (file no. I ZB 43/11), the Federal Supreme Court decided on the question as to whether an administrative fine is to be imposed on the managing director of a limited liability company [GmbH] if previously, both the GmbH as well as its managing director were ordered, upon…
On 20 March 2012, the Tribunal de Grande Instance of Paris rendered its decision in the case relating to raloxifene, a molecule useful for treating or preventing osteoporosis in post-menopausal women, opposing Teva to Eli Lilly. This decision raises many questions, first concerning drug patents in particular (patentability of second medical use, patentability of the resolution of…
Today it seems to be commonplace that without a patent system people would be less motivated to invest time and resources into making inventions that may foster technological progress. What is less clear is where the origins of this concept should be traced. Ancient Greece, which made so many contributions to knowledge, neglected the practical…
The Paris Court of Appeal clarified the conditions to be assessed by the Court in order to grant an interlocutory injunction pursuant to Article L. 615-3 of the French Intellectual Property Code. A summary of this case will be posted on http://www.KluwerIPCases.com
The following summarises another interesting decision for the rejuvenated Patents County Court which is continuing to flourish as a forum for smaller intellectual property disputes of all kinds. Merck is the proprietor of European Patent (EP (UK) 1 480 717) which, in relation to the product montelukast (Singulair, used for the treatment of adult and…
The Court of Appeal confirms the revocation by the District Court of a patent relating to a coformulation of timolol and dorzolamide for the treatment of glaucoma , for lack of inventive step. The combination of these two substances was disclosed before the priority date as a concomitant therapy. The skilled person would turn this…
